Actionable Stock Market Trading Newswire. Built for Traders, by Traders.
All news is property of their respective owners.

Home Newsfeeds ‘UK to design ‘digital pound’ that could fend off future private tech rival’ -FT

‘UK to design ‘digital pound’ that could fend off future private tech rival’ -FT

https://www.ft.com/content/5730d761-2a7e-470f-8bee-953b64f7775d

byMichael Horton

February 6, 2023

1 minute read

https://www.ft.com/content/5730d761-2a7e-470f-8bee-953b64f7775d

Truce!! Shake Shack Reaches Agreement With Activist Investor Engaged Capital

By Shivani Kumaresan

May 16, 9:12 AM

Shake Shack Inc (NYSE:SHAK) has entered a cooperation agreement with Engaged Capital, LLC, one of its largest stockholders. As part of…

DPZ

News

U.S. LNG Exporter Freeport Has Retracted Its Force Majeure Declaration After June Explosion; Preliminary Findings On Root Cause Of Explosion Show That Incident Was Not A Result Of Force Majeure

By Benzinga Newsdesk

August 10, 11:01 AM

-Reuters

LNG

ALX Oncology Realigns Executive Leadership Team, Jason Lettmann Appointed As Chief Executive Officer

By Happy Mohamed

September 6, 8:17 AM

ALX Oncology Holdings Inc., ("ALX Oncology" or "the Company") (NASDAQ:ALXO), an immuno-oncology company developing therapies that block the CD47 immune checkpoint pathway, today announced that Jason

ALXO

Citigroup Maintains Buy on Calliditas Therapeutics, Raises Price Target to $79

By Benzinga Newsdesk

February 24, 8:35 AM

Citigroup analyst Yigal Nochomovitz maintains Calliditas Therapeutics (NASDAQ:CALT) with a Buy and raises the price target from $76 to $79.

CALT

‘UK to design ‘digital pound’ that could fend off future private tech rival’ -FT

Related Posts

Truce!! Shake Shack Reaches Agreement With Activist Investor Engaged Capital

U.S. LNG Exporter Freeport Has Retracted Its Force Majeure Declaration After June Explosion; Preliminary Findings On Root Cause Of Explosion Show That Incident Was Not A Result Of Force Majeure

ALX Oncology Realigns Executive Leadership Team, Jason Lettmann Appointed As Chief Executive Officer

Citigroup Maintains Buy on Calliditas Therapeutics, Raises Price Target to $79